114 related articles for article (PubMed ID: 29359868)
1. Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Bielen R; Robaeys G; Schelfhout S; Monbaliu D; Van der Merwe S; Pirenne J; Nevens F
Transpl Int; 2018 May; 31(5):503-509. PubMed ID: 29359868
[TBL] [Abstract][Full Text] [Related]
2. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
3. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
De Simone P; Romagnoli R; Tandoi F; Carrai P; Ercolani G; Peri E; Zamboni F; Mameli L; Di Benedetto F; Cillo U; De Carlis L; Lauterio A; Lupo L; Tisone G; Prieto M; Loinaz C; Mas A; Suddle A; Mutimer D; Roche B; Wartenberg-Demand A; Niemann G; Böhm H; Samuel D
Transplantation; 2016 Jul; 100(7):1507-12. PubMed ID: 27023394
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
5. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
[TBL] [Abstract][Full Text] [Related]
6. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
Marzano A; Marengo A; Andreone P; Volpes R; Canova D; Cursaro C; Riili A; Fiorentino B; Bacci M; Guazzini S; Burra P
Minerva Med; 2010 Dec; 101(6):373-83. PubMed ID: 21196896
[TBL] [Abstract][Full Text] [Related]
8. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
[TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
11. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
13. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
14. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
[TBL] [Abstract][Full Text] [Related]
15. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.
Tanaka T; Benmousa A; Marquez M; Therapondos G; Renner EL; Lilly LB
Clin Transplant; 2012; 26(5):E561-9. PubMed ID: 23061767
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
McGonigal KH; Bajjoka IE; Abouljoud MS
Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
[TBL] [Abstract][Full Text] [Related]
18. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
20. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
Radhakrishnan K; Chi A; Quan DJ; Roberts JP; Terrault NA
Transplantation; 2017 Sep; 101(9):2079-2082. PubMed ID: 28880197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]